Abstract titles reveal some of ASCO’s key datasets.

The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.

Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.

But Repare and Black Diamond still have rebuilding to do.